Episode 140 - Megan McGill - CEO Brenig Therapeutics

Today’s guest brings a rare blend of medicine, science, and strategy to the frontlines of biotech innovation.

Dr. Megan McGill is a physician-scientist and biotech leader with over two decades of experience spanning clinical medicine, neuroscience research, and drug development. Trained as both an MD and PhD, her work has focused deeply on understanding the brain—particularly the mechanisms behind neurodegenerative diseases like Parkinson’s.

But Megan didn’t stop at the lab or the clinic. She’s also worked at the highest levels of strategy consulting with McKinsey & Company, and held leadership roles at cutting-edge biotech firms like Regenxbio and BridgeBio, helping translate scientific breakthroughs into real therapies for patients.

Today, she serves as CEO of Brenig Therapeutics, where she’s leading efforts to develop next-generation, AI-enabled treatments targeting the underlying biology of neurological disease.

In this conversation, we’ll explore her journey from medicine to biotech leadership, the future of drug development, women in leadership positions and what it takes to turn scientific insight into life-changing innovation.